Cases & Deals

  • Home
  • Practices
  • Celgene asserts its REVLIMID® patents against Cipla under Hatch-Waxman Act

Share

Celgene asserts its REVLIMID® patents against Cipla under Hatch-Waxman Act

September 2018

Client(s) Celgene Corporation

Jones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Cipla Limited in Hatch-Waxman litigation matters involving Cipla’s proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.

Celgene Corporation v. Cipla Limited, No. 2-17-cv-06163, 2-18-cv-08964 (D.N.J.)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.